Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sulzer Medica launches biological implant in Europe:

This article was originally published in Clinica

Executive Summary

Sulzer Medica has launched its first biological implant, the collagen meniscus implant, CMI, in Europe. The product is a sponge-like structure of highly purified collagen. The porous structure of the CMI serves as a scaffold to support ingrowth of cells and the formation of new meniscus tissue. The product was developed jointly with Redwood, California-based ReGen Biologics, in which Sulzer has a minority holding. Sulzer, of Winterthur, Switzerland, has marketing and distribution rights to the product worldwide, excluding the US.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT075855

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel